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‘Stealth’ liposomes with a poly(ethylene glycol) (PEG) coating are frequently studied for drug delivery and diagnostic purposes because of
their prolonged blood circulation kinetics. However, several recent reports have demonstrated that PEG-liposomes are rapidly cleared at single low
lipid doses (<1 μmol/kg) and upon repeated administration (time interval between the injections 5 days–4 weeks). Recently, poly(amino acid)-
based stealth liposome coatings have been developed as alternative to the PEG-coating. In this study, the pharmacokinetic behavior of liposomes
coated with the poly(amino acid) poly(hydroxyethyl-L-asparagine) (PHEA) was evaluated at low lipid doses and upon repeated administration in
rats. Blood circulation times and hepatosplenic localization of PHEA-liposomes were assessed after intravenous injection. When administered at a
dose of 0.25 μmol/kg or less, PHEA-liposomes showed significantly longer blood circulation times than PEG-liposomes. A second dose of
PHEA-liposomes 1 week after the first injection was less rapidly cleared from the circulation than a second dose of PEG-liposomes. Although the
mechanisms behind these observations are still not clear yet, the use of PHEA-liposomes appears beneficial when single low lipid doses and/or
repeated dosing schedules are being applied.
© 2006 Elsevier B.V. All rights reserved.Keywords: Long-circulating liposomes; Pharmacokinetics; Poly(ethylene glycol); Poly(amino acid)s; Accelerated blood clearance; Repeated administration1. Introduction
Liposomes have been extensively studied for drug delivery
and diagnostic purposes [1]. Their ability to extravasate at sites
with increased vascular permeability, for example in solid
tumors and inflamed tissue, enables selective targeting to these
sites (enhanced permeability and retention (EPR) effect) [2].
Steric stabilization of liposomes with hydrophilic polymers
such as poly(ethylene glycol) (PEG) results in a reduced uptake
by cells of the mononuclear phagocyte system (MPS) leading to
prolonged circulation times and thereby to an increased local-
ization in the pathological site [3–5]. With several formulations
on the market and in clinical trials, and numerous more in pre-
clinical evaluation, PEG-liposomes remain the gold standard for
long-circulating nanoparticles [5].⁎ Corresponding author. Tel.: +31 30 2536898; fax: +31 30 2517839.
E-mail address: b.romberg@pharm.uu.nl (B. Romberg).
0005-2736/$ - see front matter © 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamem.2006.12.005There are, however, several drawbacks in the application of
PEG-liposomes, among which pharmacokinetic irregularities
observed in animal models at low lipid doses and upon repeated
administration [6–12]. In humans, irregularities at low lipid
doses have been reported [7]. Although PEG-liposomes show
dose-independent pharmacokinetics over a broad lipid dose
range (4–400 μmol/kg) [13], this does not hold true at much
lower lipid doses which are utilized for diagnostic imaging of
e.g. tumors and sites of inflammation [7,14]. Several studies
have shown that PEG-liposomes are rapidly cleared at such
low lipid doses [6,7]. In rats, lipid doses lower than 0.03 μmol/kg
were prone to accelerated clearance from the bloodstream.
In humans, this phenomenon was observed at a lipid dose of
0.1 μmol/kg [7]. Despite several attempts to unravel the under-
lying cause, the mechanism of this phenomenon is still poorly
understood. The faster disappearance from the circulation is
accompanied by an increased accumulation in liver and spleen
suggesting a role for hepatosplenic macrophages. Therefore, the
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circulation has been discussed, which induces rapid clearance of
PEG-liposomes at low lipid doses and is depleted at higher
liposome doses [14].
Besides at low lipid doses, rapid clearance was also observed
upon repeated administration of PEG-liposomes [14]. This phe-
nomenon has been referred to as ‘accelerated blood clearance’
(ABC). Several groups reported that a second dose of PEG-
liposomes was rapidly cleared when administered within a
certain time interval after the first dose; this was seen in
different animal species [8–12]. In rats, dramatically decreased
circulation times and elevated hepatosplenic uptake were found
in case of 99mTc-labeled PEG-liposomes at a dose of 5 μmol/kg
with an interval of 5 days to 4 weeks between the injections [9].
Time interval, doses, and liposome characteristics were
different in the studies in which this ABC phenomenon was
observed. Liposome size, surface charge, PEG density, and
PEG molecular weight were reported to be of importance [14].
At doses higher than 50 μmol/kg pharmacokinetic irregularities
did not occur in rats. Also in the case of repeated administration,
the mechanism behind the observed pharmacokinetic changes
has not been revealed yet. The involvement of serum factors was
suggested, however, there is no consensus about their identity
[14].
Recently, biodegradable poly(amino acid) (PAA)-lipid con-
jugates were successfully applied to prolong liposome circula-
tion times. Circulation kinetics and biodistribution pattern of
PAA-liposomes were similar to those of PEG-liposomes after
single-dose administration of 25 μmol/kg [15,16]. The chemical
nature of PAA, however, is very different from PEG. Therefore,
it is likely that there are also differences in the nature of the
steric stabilization layers formed by the respective materials on
the surface of the liposomes. This, in turn, may lead to differ-
ences in pharmacokinetic behavior when administered repeat-
edly or at low lipid doses.
Both the rapid clearance at low lipid doses and upon repeated
administration limit the applicability of PEG-liposomes. In the
present study we investigated in rats the pharmacokinetic beha-
vior of liposomes prepared with the poly(amino acid)-lipid
conjugate poly(hydroxyethyl-L-asparagine)-succinyldiocta-
decylamine (PHEA-DODASuc) at low lipid doses and uponFig. 1. Molecular structure of poly(hydroxyethyl-L-asparaginerepeated administration. The results were compared to those
obtained with PEG-liposomes. PHEA-liposomes appeared to
show superior pharmacokinetic properties at low lipid doses and
upon repeated administration.
2. Materials and methods
2.1. Materials
PHEA-DODASuc (Fig. 1, average MW=3000 Da, determined by NMR and
MALDI-ToF MS, corresponding with an average degree of polymerization of
15) was synthesized as described previously [15]. Dipalmitoylphosphatidylcho-
line (DPPC), egg phosphatidylcholine (EPC), egg phosphatidylglycerol (EPG)
and polyethylene glycol-distearoylphosphatidylethanolamine (PEG-DSPE)
were purchased from Lipoid GmbH, Ludwigshafen, Germany. Cholesterol
was obtained from Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands.
[3H]-Cholesteryl oleylether was a product of Amersham, Roosendaal, The
Netherlands. Ultima Gold liquid scintillation cocktail and Solvable tissue solu-
bilizer were purchased from Perkin Elmer BioScience B.V., Groningen, The
Netherlands. All other reagents were of analytical grade.
2.2. Animals
Male outbred Wistar rats, weighing approximately 250 g, were obtained
from Harlan Nederland (Horst, The Netherlands). They were housed in groups
of 4 and had free access to water and rat chow. All animal experiments were
performed according to national regulations and approved by the local animal
experiments ethical committee.
2.3. Liposome preparation
Liposomes were prepared by a film-extrusion method [17]. For the
pharmacokinetic study involving single low lipid doses, EPC/EPG liposomes
(1:1) with 5 mol% of PHEA-DODASuc or PEG-DSPE were prepared at
two different lipid concentrations (20 and 0.2 μmol total lipid/mL, total
volume of 2.5 mL). Lipids were dissolved in ethanol in 50 mL round-
bottom flasks. To each formulation 20 μL of the non-degradable lipid phase
marker [3H]-cholesteryl oleylether were added (approximately 740 kBq).
Lipid films were obtained by evaporation of the solvent under a stream of
nitrogen. The lipid films were hydrated in 5mLHBS (5mMHEPES, 0.9%NaCl,
pH 7.4) yielding total lipid concentrations of 20 and 0.2 μmol/mL. Liposomes
were sized by sequential extrusion through two stacked polycarbonate filters
(Poretics, Livermore, CA, USA, 400, 200, and 100 nm pore size) with a high-
pressure extrusion device. The formulation prepared at a concentration of
0.2 μmol/mL was divided into two equal parts, and one part was further diluted
1:10 in HBS, yielding a lipid concentration of 0.02 μmol/mL.
For the pharmacokinetic study involving repeated administration, lipo-
somes composed of DPPC/cholesterol/coating polymer in a molar ratio of)-succinyldioctadecylamine (PHEA-DODASuc, n ≈15).
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concentrations of 5 μmol/mL (for a lipid dose of 5 μmol/kg rat body weight) or
12.5 μmol/mL (for a lipid dose of 10 and 20 μmol/kg rat body weight). The
[3H]-cholesteryl oleylether label was added only to the liposome formulations
to be monitored for circulation times and biodistribution. For the composition
of the different formulations see Table 1.
2.4. Liposome characterization
The mean particle size and polydispersity index of the liposome dispersions
(diluted 1:100 with HBS) were determined by dynamic light scattering using a
Malvern ALV/CGS-3 Goniometer. The lipid content of the liposomal
dispersions was assessed by phospholipid quantification according to Rouser
et al. [18]. Radioactivity of the liposomal dispersions was assayed in an Ultima
Gold liquid scintillation cocktail (dilution of 1:1000) and counted in a Packard
Tricarb 2200 CA liquid scintillation counter. Liposome preparations were stored
at 4 °C and used within 1 week after preparation.
2.5. Pharmacokinetics
For the pharmacokinetic study involving low lipid doses, single doses of the
liposomal preparations containing 25, 0.25 or 0.025 μmol total lipid/kg body
weight were administered via the tail vein. Blood samples of 150 μL were
collected from the tail vein of each rat at the following time points: immediately
after injection (opposite vein to injection vein) and at 1, 4, 8, 24, and 48 h after
injection. For the pharmacokinetic study involving repeated administration,
either no priming dose or a priming dose of 5, 10, or 20 μmol/kg body weight of
non-labeled liposomes was given. Seven days later the corresponding labeled
formulations were injected at the same dose. Blood samples of 150 μL were
collected as described above immediately after injection (from the opposite tail
vein) and at 1, 4, 8, 24, and 48 h after injection. To 100 μL of the blood samples,
100 μL Solvable tissue solubilizer and 100–200 μL 35% hydrogen peroxide to
bleach the samples were added and samples were incubated at room temperature
overnight. Samples were diluted in 10 mL Ultima Gold scintillation cocktail and
counted for radioactivity with a Packard Tricarb 2200CA liquid scintillation
counter.
For the study involving repeated administration, liver and spleen were
dissected at 48 h post-injection and homogenized in 25 mL and 5 mL water,
respectively, using an Ultra-Turrax T8 (IKA Labortechnik GmbH, Staufen,
Germany) at 25000 rpm for approximately 30 s. To 0.5 mL of the liver
homogenate and 1 mL of the spleen homogenate, 200 μL of Solvable tissue
solubilizer and 200 μL 35% hydrogen peroxide were added and incubated at
room temperature until the tissue was dissolved (usually overnight). After
adding 10 mL of Ultima Gold scintillation cocktail, radioactivity was counted as
described for the blood samples. Besides tissue and blood samples, also the




Lipid dose: 25 μmol/kg PEG-liposomes EPC
PHEA-liposomes EPC
Lipid dose: 0.25 and 0.025 μmol/kg PEG-liposomes EPC
PHEA-liposomes EPC
Repeated administration study
Non-labeled dose (priming): 5 μmol/kg PEG-liposomes DPP
PHEA-liposomes DPP
Non-labeled dose (priming): 10 and 20 μmol/kg PEG-liposomes DPP
PHEA-liposomes DPP
Labeled dose: 5 μmol/kg PEG-liposomes DPP
PHEA-liposomes DPP
Labeled dose: 10 and 20 μmol/kg PEG-liposomes DPP
PHEA-liposomes DPP2.6. Data analysis
Blood concentrations of liposomes at the different time points were
calculated from the radioactivity of the blood samples as the percentage of the
radioactivity measured immediately after injection (% injected dose). For the
blood samples, a Q-test for identification of outliers was applied. From the blood
concentration–time curves, area under the curve values were calculated for the
analyzed time interval from zero to 48 h (AUC0–48h [μmol/kg×h]). Differences
in AUCs were compared by a two-tailed Student's t-test assuming equal
variances with a 95% confidence interval. Differences were considered
significant when the p-value was less than 0.05. The percentage of the injected
dose in the organs was calculated by dividing the total radioactivity of the organs
by the radioactivity of the injected liposome amount.
3. Results
3.1. Liposome characteristics
Table 1 shows the characteristics of the liposome formula-
tions used in this study. The mean size of the liposomes ranged
from 110 to 150 nm. The polydispersity index (PD) was ≤0.12,
indicating a narrow size distribution. All preparations were
physically stable during storage at 4 °C for at least 1 week.
3.2. Pharmacokinetics at low lipid doses
To evaluate the possibility of alterations in circulation time of
PHEA-liposomes occurring when low lipid doses are applied,
radiolabeled PHEA- (EPC/EPG/PHEA-DODASuc) and PEG-
liposomes (EPC/EPG/PEG-DSPE) were injected i.v. at lipid
doses of 25, 0.25, and 0.025 μmol/kg. The resulting circulation
kinetics and the AUC0–48h values are presented in Fig. 2. For
the high dose of 25 μmol/kg, the circulation behavior of the
PEG- and the PHEA-liposomes were comparable, as reflected
by similar blood concentration–time curves and AUC0–48h
values. At the lower dose of 0.25 μmol/kg, PEG-liposomes
were cleared more rapidly from the bloodstream than at
25 μmol/kg. PHEA-liposomes, however, show similar circula-
tion kinetics after injection of 25 and 0.25 μmol/kg. Twenty-
four hours after administration of 0.25 μmol/kg, 24.5% of the
PHEA-liposomes were detected in the blood circulation, versusposition (molar ratio) Mean size [nm] PD
/EPG/PEG-DSPE 1.425:1.425:0.15 140 0.07
/EPG/PHEA-DODASuc 1.425:1.425:0.15 125 0.10
/EPG/PEG-DSPE 1.425:1.425:0.15 130 0.10
/EPG/PHEA-DODASuc 1.425:1.425:0.15 110 0.12
C/cholesterol/PEG-DSPE 1.85:1:0.15 125 0.04
C/cholesterol/PHEA-DODASuc 1.85:1:0.15 125 0.06
C/cholesterol/PEG-DSPE 1.85:1:0.15 135 0.06
C/cholesterol/PHEA-DODASuc 1.85:1:0.15 130 0.04
C/cholesterol/PEG-DSPE 1.85:1:0.15 145 0.06
C/cholesterol/PHEA-DODASuc 1.85:1:0.15 145 0.02
C/cholesterol/PEG-DSPE 1.85:1:0.15 140 0.05
C/cholesterol/PHEA-DODASuc 1.85:1:0.15 135 0.06
Fig. 2. Comparative pharmacokinetics of PHEA- and PEG-liposomes at lipid doses of 25 μmol/kg, 0.25 μmol/kg, and 0.025 μmol/kg. (a) Circulation kinetics of
PHEA- (EPC/EPG/PHEA-DODASuc) (●) and PEG-liposomes (EPC/EPG/PEG-DSPE) (■) (% injected dose vs. time). (b) Area under the curve (AUC0–48h) values
calculated from (a). All results are expressed as mean±SD (n=3–4). **p<0.01; n.s.=not significant.
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PHEA-liposomes was approximately twofold higher than that
of the PEG-liposomes. At the lowest dose of 0.025 μmol/kg, the
difference in pharmacokinetics of PHEA- and PEG-liposomes
was maintained; the difference in the AUC0–48h values was
about 2.5-fold.
3.3. Pharmacokinetics and biodistribution at single and
repeated administration
The effect of repeated administration of PHEA-liposomes
(DPPC/cholesterol/PHEA-DODASuc) on pharmacokinetics
and biodistribution was evaluated by administering liposomes
i.v. either as a single dose (labeled dose) or injecting twice
(priming and labeled dose) with a time interval of 7 days
between the two injections. Lipid doses of 5, 10, and 20 μmol/kg
were investigated. For comparison, PEG-liposomes (DPPC/
cholesterol/PEG-DSPE) were also studied using the same expe-
rimental conditions. Fig. 3 presents the blood concentration–
time curves and the ratios of the AUC0–48h of the second
injection to the AUC0–48h of the first injection (AUC2nd/1st). If
the AUC2nd/1st equals one, no differences in circulation times
between the liposomes given at the second and the first injectionwere observed. If the AUC2nd/1st is smaller than one, the
liposomes given at the second injection were cleared more
rapidly from the circulation than those given at the first
injection. At the lipid dose of 5 μmol/kg the first dose of PEG-
liposomes yielded prolonged circulation times, whereas lipo-
somes administered at the second dose were cleared very
rapidly, with only 2.3% of the liposomes left in the circulation at
1 h after administration. The AUC2nd/1st was 0.04, indicating
that the AUC0–48h of the second injection was very small as
compared to the AUC0–48h of the first injection. In the case of
administration of 5 μmol/kg PHEA-liposomes, the second dose
circulated significantly longer than the second dose of PEG-
liposomes, with 52.8% of the liposomes still circulating in the
blood 1 h after injection. The AUC0–48h of the second injection
was about half of the AUC0–48h of the first injection
(AUC2nd/1st=0.47). While at 10 μmol/kg the second dose of
PEG-liposomes was still very rapidly removed from the
circulation, the second dose of PHEA-liposomes showed
enhanced circulation times when compared with the lower
dose of 5 μmol/kg. The AUC2nd/1st of the PHEA-liposomes was
0.67. In case of the dose of 20 μmol/kg, the second dose of
PHEA-liposomes circulated as long as the first dose, as reflected
by an AUC2nd/1st of one. The second dose of PEG-liposomes
Fig. 3. Effect of the lipid dose on pharmacokinetic behavior of PHEA- and PEG-liposomes after first and second injection. (a) Circulation kinetics of PHEA- (DPPC/
cholesterol/PHEA-DODASuc) and PEG-liposomes (DPPC/cholesterol/PEG-DSPE) (% injected dose vs. time). Closed symbols represent the results after the first
injection, open symbols those after the second injection of liposomes. (b) Ratio of the AUC0–48h of the second injection to the AUC0–48h of the first injection
(AUC2nd/1st) at the different lipid doses. AUC0–48h values were calculated from (a). Filled bars represent the AUC2nd/1st of PEG-liposomes, dotted bars represent
the AUC2nd/1st of PHEA-liposomes. All results are expressed as mean±SD (n=3–4). *p<0.05; n.s.=not significant.
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compared to the second dose of 5 and 10 μmol/kg, but by far
shorter than the second dose of PHEA-liposomes.
Fig. 4 shows the localization of PEG- (DPPC/cholesterol/
PEG-DSPE) and PHEA-liposomes (DPPC/cholesterol/PHEA-DODASuc) in liver and spleen at 48 h after administration. The
ratios of the percentage of injected dose of the second injection
to the percentage of the injected dose of the first injection
recovered in the two organs were calculated (% ID2nd/1st). If this
ratio is smaller than one, the second dose was taken up by the
Fig. 4. Hepatosplenic localization of PHEA- and PEG-liposomes at 48 h after injection: ratio of the percentage of injected dose of the second injection to the percentage
of injected dose of the first injection (% ID2nd/1st). Filled bars represent the % ID2nd/1st of PEG-liposomes (DPPC/cholesterol/PEG-DSPE), dotted bars represent the %
ID2nd/1st of PHEA-liposomes (DPPC/cholesterol/PHEA-DODASuc). All results are expressed as mean±SD (n=3–4).
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a larger fraction of the second dose was taken up as compared to
the fraction of the first dose. Remarkably, the % ID2nd/1st values
observed for the liver are above one for both formulations at all
dose levels, indicating that the second dose of liposomes is
primarily taken up by the liver, whereas the spleen is less
involved in processing of the second dose when compared to the
first dose as demonstrated by splenic % ID2nd/1st values below
one. The differences in biodistribution between the first and the
second dose diminished at higher doses, especially in the case of
the PHEA-liposomes. In both organs the % ID2nd/1st of 20 μmol/
kg PHEA-liposomes is close to one, showing that there are no
differences in liver and spleen distribution between the first and
the second injection at this dose level.
4. Discussion
In recent years it has been recognized that PEG-liposomes are
not as ‘stealth’ in the biological environment as was generally
assumed. Although stealth coatings reduce rapid clearance of the
liposomes from the circulation, extensive binding of blood
proteins to the liposome surface does occur after intravenous
administration [19]. Hence, the long circulation time of PEG-
liposomes is not necessarily a direct result of a non-specific
reduction of protein adsorption as often claimed, but likely
related to a combination of several mechanisms [19,20]. For
example, so-called dysoponins might contribute to the stealth
behavior. They have been hypothesized to bind to the liposome
surface in the circulation, thereby repelling binding of opsonic
factors, and as a consequence reducing the uptake of the lipo-
somes by phagocytic cells. Besides the observation of extensive
binding of blood proteins to the PEG-liposome surface, pharma-
cokinetic irregularities, such as the ABC phenomenon, in case of
repeated administration of PEG-liposomes and enhanced clear-
ance at low lipid doses additionally demonstrate that PEG-
liposomes are not ‘invisible’ in vivo [14].
The present study was conducted to investigate if liposomes
coated with the new poly(amino acid)-coating PHEA lack the
pharmacokinetic irregularities observed for PEG-liposomes
upon repeated administration and at low lipid dose. Our resultswith lipid doses ≤0.25 μmol/kg body weight clearly show that
PHEA-liposomes have superior pharmacokinetic behavior at
single low lipid doses as compared to PEG-liposomes. The
rapid clearance of PEG-liposomes at low lipid doses is likely
mediated by a pool of opsonic factors that interact with PEG-
liposomes and induce phagocytosis [19]. At higher lipid doses,
the influence of this relatively low amount of opsonic factors
becomes more limited and the majority of the administered
liposomes will be long-circulating. The higher the lipid dose,
the less this opsonization effect will be detectable in the overall
circulation profile. The theory of a limited pool of opsonins is in
agreement with the generally observed finding that a small
fraction of PEG-liposomes administered at higher lipid doses is
rapidly cleared within 60 min after administration [14]. Our
observation that low doses of PHEA-coated liposomes show
relatively long circulation times suggests that the process of
opsonization is rather different for PHEA- and PEG-liposomes.
A lower affinity of the opsonins involved for the PHEA-lipo-
somes as compared to PEG-liposomes could result in extended
circulation times. Moreover, due to the very different chemical
nature of the PHEA-molecule in comparison to PEG, the type
and/or adsorbed amount of opsonins may be substantially diffe-
rent as a reflection of differences in chemical structure, hydro-
philicity, length, and flexibility. Further investigations on the
protein adsorption pattern will shed more light on the mecha-
nism behind the superior circulation time of PHEA-liposomes at
low lipid doses.
As aforementioned, repeated administration of PEG-lipo-
somes can lead to rapid clearance of the subsequent injections as
compared to the first injection (ABC phenomenon). Besides
being favorable at single low lipid dose, PHEA-liposomes are
also much less susceptible for the ABC phenomenon when
compared to PEG-liposomes by showing superior circulation
kinetics upon repeated administration at the dose range of 5–
20 μmol/kg. A time interval of 7 days between the first and
second injection was chosen in this study as at this interval the
clearance of a second dose of PEG-liposomes was most rapid in
rats [9]. At much longer or shorter time intervals the effect was
attenuated. The ABC phenomenon can be induced by a variety
of liposome formulations, including liposome types, which lack
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appeared also not to be an essential requirement for the rapid
clearance of liposomes given as the second dose [8]. At present,
there is no consensus about the mechanism underlying the ABC
phenomenon. A role for hepatosplenic macrophages in the ABC
phenomenon has been proposed [8,9]. Several studies have
shown that in particular Kupffer cells of the liver take part in the
clearance of a second dose of liposomes. Our data on the
hepatosplenic distribution of the liposomes investigated are in
line with these observations; uptake of the second dose by
the liver was highly increased when the ABC phenomenon
was induced. Transfusable humoral serum factors have been
suggested to play a role, and also IgG or IgMhave been proposed
to be involved [9,22,23]. Recently, Ishida et al. reported on an
IgM molecule with anti-PEG activity, which binds to a second
dose of liposomes and subsequently activates the complement
system [23]. Yet, as also non-PEGylated liposomes can induce
the phenomenon, it is obvious that the mechanism behind the
ABC phenomenon is more complex, and that PHEA- and PEG-
liposomes behave differently in this regard.
The implications of the present findings for the use of the
currently approved liposomal drug formulations (e.g. the doxo-
rubicin containing PEG-liposome product Doxil®/Caelyx®) is
not clear. However, the data do suggest that in the clinical
setting, where repeated administration of liposomal drugs will
often be required, the therapeutic efficacy might be compro-
mised by an accelerated MPS clearance of repeatedly injected
liposome-based therapeutics. Furthermore, a rapid and exten-
sive uptake by hepatosplenic organs as observed after admin-
istration of PEG-liposomes may increase the toxicity towards
these organs conferred by increased accumulation of the incor-
porated drugs.
In conclusion, although the mechanistic details are still
largely obscure, this paper highlights that the use of PHEA-
coated long-circulating liposomes may be beneficial when
single low lipid doses and/or repeated dosing schedules are
being applied.
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